ASCO: Merck KGaA, Pfizer's Bavencio combo misses survival mark in crowded kidney cancer space

Five years after scoring an FDA approval to treat newly diagnosed advanced kidney cancer, the combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta has failed on the overall survival endpoint of a phase 3 trial.